HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Rockwell Medical (NASDAQ:RMTI) but lowers the price target from $11 to $9.

March 25, 2024 | 10:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rockwell Medical's Buy rating is maintained by HC Wainwright & Co., but the price target is reduced from $11 to $9.
The maintenance of a Buy rating suggests continued analyst confidence in Rockwell Medical's fundamentals or growth prospects. However, the reduction in the price target could reflect adjustments in market conditions, company performance expectations, or both. This mixed signal is likely to have a neutral short-term impact on the stock price as positive sentiment from the maintained Buy rating could be offset by the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100